Janssen initiates study on erdafitinib intravesical delivery for bladder cancer in Japan
A clinical trial is underway to assess the tolerability of an intravesical delivery system for erdafitinib in Japanese patients with bladder cancer.
Asset / Drug
Drug and asset intelligence for erdafitinib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.